Cyfuse Biomedical K.K. Statistics
Want to see JP:4892 full AI Analyst Report?
Cyfuse Biomedical K.K. (4892) Stock Statistics & Valuation Metrics
Total Valuation
Cyfuse Biomedical K.K. has a market cap or net worth of JPY 5.19B. The enterprise value is JPY 3.38B.
- Market Cap
- JPY 5.19B
- Enterprise Value
- JPY 3.38B
Share Statistics
Cyfuse Biomedical K.K. has 10,092,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 10,092,100
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Cyfuse Biomedical K.K.’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -20.35%.
- Return on Equity (ROE)
- -0.28
- Return on Assets (ROA)
- -0.18
- Return on Invested Capital (ROIC)
- -20.35%
- Return on Capital Employed (ROCE)
- -0.24
- Revenue Per Employee
- 10.04M
- Profits Per Employee
- -33.21M
- Employee Count
- 23
- Asset Turnover
- 0.05
- Inventory Turnover
- 1.72
Valuation Ratios
The current PE Ratio of Cyfuse Biomedical K.K. is -6.28. Cyfuse Biomedical K.K.’s PEG ratio is -0.30.
- PE Ratio
- -6.28
- PS Ratio
- 16.86
- PB Ratio
- 1.96
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.30
Income Statement
In the last 12 months, Cyfuse Biomedical K.K. had revenue of 231.00M and earned -763.84M in profits. Earnings per share was -86.78.
- Revenue
- 231.00M
- Gross Profit
- 78.40M
- Operating Income
- -828.18M
- Pretax Income
- -761.30M
- Net Income
- -763.84M
- EBITDA
- -792.68M
- Earnings Per Share (EPS)
- -86.78
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Cyfuse Biomedical K.K. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -15.38%
Stock Price Statistics
- Beta
- 0.46
- 52-Week Price Change
- -12.29%
- 50-Day Moving Average
- 609.04
- 200-Day Moving Average
- 599.60
- Relative Strength Index (RSI)
- 34.89
- Average Volume (3m)
- 50.01K
Important Dates
Cyfuse Biomedical K.K. upcoming earnings date is Feb 12, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Feb 12, 2027
- Ex-Dividend Date
- ―
Financial Position
Cyfuse Biomedical K.K. as a current ratio of 4.54, with Debt / Equity ratio of 47.58%
- Current Ratio
- 4.54
- Quick Ratio
- 4.44
- Debt to Market Cap
- 0.25
- Net Debt to EBITDA
- 3.05
- Interest Coverage Ratio
- -58.00
Taxes
In the past 12 months, Cyfuse Biomedical K.K. has paid 2.54M in taxes.
- Income Tax
- 2.54M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Cyfuse Biomedical K.K. EV to EBITDA ratio is -6.16, with an EV/FCF ratio of 0.00.
- EV to Sales
- 14.97
- EV to EBITDA
- -6.16
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Cyfuse Biomedical K.K. has JPY 3.39B in cash and marketable securities with JPY 1.23B in debt, giving a net cash position of JPY 2.16B billion.
- Cash & Marketable Securities
- JPY 3.39B
- Total Debt
- JPY 1.23B
- Net Cash
- JPY 2.16B
- Net Cash Per Share
- JPY 213.88
- Tangible Book Value Per Share
- JPY 260.21
Margins
Gross margin is 47.49%, with operating margin of -253.17%, and net profit margin of -260.19%.
- Gross Margin
- 47.49%
- Operating Margin
- -253.17%
- Pretax Margin
- -259.36%
- Net Profit Margin
- -260.19%
- EBITDA Margin
- -243.01%
- EBIT Margin
- -253.17%
Analyst Forecast
The average price target for Cyfuse Biomedical K.K. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 364.72%
- EPS Growth Forecast
- 18.43%
Scores
- Smart Score
- ―
- AI Score
- 42

